University of Chicago Leukemia Program shared a post on X:
“A beautiful presentation by Sam Yates characterizing data led by him and co-author Anand Patel focused on time to treatment in newly diagnosed AML receiving HMA-VEN!
Time to treatment was not a detriment to OS!”
